Letters NICE guidance on ADHD

NICE recommendations are not evidence based and could expose many to unnecessary harm

BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2284 (Published 28 October 2008) Cite this as: BMJ 2008;337:a2284
  1. Sami Timimi, consultant child and adolescent psychiatrist1,
  2. Jon Jureidini, consultant child and adolescent psychiatrist2,
  3. Jonathan Leo, associate professor of neuroanatomy3
  1. 1Lincolnshire Partnership Foundation NHS Trust, Lincoln LN4 2HN
  2. 2Women’s and Children’s Hospital, Adelaide, Australia
  3. 3Lincoln Memorial University, Harrogate, USA
  1. stimimi{at}talk21.com

    The National Institute for Health and Clinical Excellence’s (NICE’s) single most important recommendation is for medication to be used as a first line treatment in “severe” attention-deficit/hyperactivity disorder (ADHD).1 Like other systematic reviews of ADHD medication treatment, NICE notes the inadequate reporting of study methodology, possible bias, limited reliability of results, and inadequate data regarding adverse events, correctly …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe